Why They Tried to Bury Vitamin B17: The Hidden Economics of Healing * 100PercentFedUp.com * by Jan James

Why would a simple nutrient found in Apricot Seeds spark decades of controversy, censorship, and fear? Why has Vitamin B17—also known as amygdalin or Laetrile—been labeled “dangerous,” while toxic chemotherapy drugs remain unquestioned as the only legitimate treatment?

The truth isn’t hidden in the lab—it’s hidden in the ledger. What’s at stake isn’t science versus myth; it’s profit versus prevention.

Cancer’s Cash Machine

Cancer is not just a disease—it’s an industry worth more than $200 billion a year in the United States alone. Every infusion, radiation session, and prescription pill adds to that total.

Natural compounds like Vitamin B17, on the other hand, can’t be patented. They can’t be owned, trademarked, or turned into recurring revenue. They represent healing without dependency, prevention without a price tag.

And that’s precisely why they’ve been targeted.

When Laetrile began showing promise through case studies and clinical reports, it threatened an entire financial ecosystem built on chronic illness. Big Pharma’s business model doesn’t reward cures—it rewards customers for life.

Why They Tried to Bury Vitamin B17: The Hidden Economics of Healing

A History Buried Beneath Bureaucracy

In the 1970s, Laetrile began gaining attention from patients who found renewed hope when conventional treatments had failed. Clinics across the U.S. and Mexico quietly reported success stories. But instead of investigating, the FDA raided doctors’ offices, confiscated supplies, and prosecuted those who used it.

Television networks and newspapers, bankrolled by pharmaceutical advertising, echoed the official script: “Laetrile is poison.” Yet thousands of patients wrote letters to Congress describing improved health, pain relief, and even remission from their conditions. Those testimonies were buried—because the real issue wasn’t toxicity. It was authority.

The Profit Pipeline

Follow the money, and the motives become clear.

Pharmaceutical companies spend billions on drug development—but only when they can secure exclusive patents. Amygdalin, being a naturally occurring compound, could never be patented. No patent means no monopoly, and no monopoly means no mega-profits.

Chemotherapy, by contrast, ensures a steady and renewable profit stream: multiple rounds, ongoing prescriptions, and endless follow-ups. The cancer economy depends on maintenance, not resolution. Laetrile threatened to collapse that model.

Media, Medicine, and Manipulation

The story of B17’s suppression can’t be told without naming its accomplices.

Major media outlets, supported heavily by pharmaceutical advertising, shaped public perception through selective reporting. Institutions like Memorial Sloan Kettering Cancer Center even concealed positive research results from their own scientists—results later exposed by whistleblower Ralph Moss. (Watch the documentary, Second Opinion: The Lie of America’s War on Cancer, here).

Meanwhile, medical education—reshaped by Rockefeller and Carnegie foundations after the 1910 Flexner Report—systematically excluded nutrition from its curriculum, ensuring doctors were trained to prescribe drugs, not food-based therapies.

This was never just a scientific debate—it was corporate control disguised as “consensus.”

What Research and Experience Reveal

Selective Activation: Amygdalin releases “bound cyanide” only inside cancer cells, where the enzyme beta-glucosidase is abundant.
Protection for Healthy Cells: Normal cells contain rhodanese, an enzyme that safely neutralizes cyanide.
Cultural Evidence: Populations like the Hunza tribe, whose traditional diets were rich in nitrilosides (B17 compounds), have historically exhibited low cancer incidence rates.
Scientific Misrepresentation: Many anti-Laetrile studies used insufficient doses or flawed experimental designs, practically ensuring failure.

A Pattern of Suppression

The campaign against Laetrile fits a broader pattern: any natural therapy that can’t be patented or monetized becomes a target. Cannabis, ozone therapy, and high-dose vitamin protocols have faced similar attacks.

The casualties of this war on natural medicine aren’t only the practitioners persecuted by the system—it’s also the millions of patients denied the chance to choose.

The threat B17 poses isn’t chemical—it’s economic. It upends the entire system by suggesting that health may not require a monthly bill.

Reclaiming the Right to Heal

For too long, the public has been taught to fear apricot seeds and distrust the natural world. It’s time to reframe the narrative.

Ask the more complex question—not “Is Laetrile safe?” but “Who benefits from keeping it illegal?”

Not “Why should we trust natural medicine?” but “Why were we taught not to?”

When we follow the money, the answers become clear. Vitamin B17’s most significant danger lies not in its chemistry but in its challenge to a trillion-dollar system built on dependency.